Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021

PRO data further support the monarchE results to date for Verzenio for the treatment of HR+, HER2- high risk early breast cancer First disclosure of patient-reported outcomes for a Phase 3 study of a CDK4 & 6 inhibitor in the adjuvant setting for HR+, HER2- early breast cancer INDIANAPOLIS , March